TRANSGENIC EXPRESSION CASSETTE FOR TREATMENT OF MUCOPOLYSACCHARIDOSIS TYPE IIIA

Provided are a transgenic expression cassette capable of treatment of mucopolysaccharidosis type IIIA, an application thereof, an optimized nucleic acid molecule encoding N-sulfoglucosamine sulfohydrolase (SGSH), a designed and optimized novel combinatorial promoter, a gene delivery system comprising the transgenic expression cassette, and a drug. The transgenic expression cassette, the gene delivery system, and the drug can effectively restore SGSH activity in patients with mucopolysaccharidosis, reduce accumulation of glycosaminoglycans, and have a good treatment effect on peripheral body diseases and central nervous system diseases of mucopolysaccharidosis type IIIA..

Medienart:

Patent

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Europäisches Patentamt - (2023) vom: 07. Dez. Zur Gesamtaufnahme - year:2023

Sprache:

Englisch

Beteiligte Personen:

XIAO XIAO [VerfasserIn]
ZHENG JING [VerfasserIn]
JIANG WEI [VerfasserIn]
DU ZENGMIN [VerfasserIn]
CHEN CHEN [VerfasserIn]
YUAN LONGHUI [VerfasserIn]
LIU QIANG [VerfasserIn]
HOU WENXIU [VerfasserIn]
WANG HUI [VerfasserIn]
ZHAO YANG [VerfasserIn]
YANG CAIFENG [VerfasserIn]
DUN YUE [VerfasserIn]
ZHENG HAO [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
bio
C12N: Microorganisms or enzymes; compositions thereof; pr (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2023-12-07, Last update posted on www.tib.eu: 2024-01-03, Last updated: 2024-01-12

Patentnummer:

WO2023231778

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA018861636